Celebrating Progress and Sharing Hope: The Leukemia & Lymphoma Society to Host Free Rocky Mountain Blood Cancer Conference for Blood Cancer Patients, Survivors and Caregivers
The Leukemia & Lymphoma Society (LLS) will be hosting its 8th Annual Rocky Mountain Blood Cancer Conference on Saturday, April 7, 2018, at the Hyatt Regency Aurora-Denver Conference Center. LLS Blood Cancer Conferences are free education events for blood cancer patients, survivors, caregivers, family members and healthcare professionals.
Shaun Willson’s story is one of daring independence and strength, as he championed through an acute myeloid leukemia diagnosis while also being the primary caregiver to his wife, Deborah, during her battle with metastatic cancer.
Quizartinib Significantly Improves Survival Over Chemotherapy in Patients with Relapsed/Refractory AML and FLT3-ITD Mutation
This is the first treatment that targets patients with AML and the FLT3-ITD mutation. In this clinical trial, patients who received quizartinib lived longer without disease progression than those receiving chemotherapy.
In recent years, new treatments for acute myeloid leukemia have improved outcomes. In 2017, 2 new drugs were approved for patients with this type of blood cancer linked to a specific biomarker.
Cancer BiomarkersFDA Approvals, News & UpdatesLeukemiaNewsworthy
This is the first time the FDA has used minimal residual disease (MRD) as a biomarker to approve a specific treatment for patients with acute lymphoblastic leukemia (ALL).
New therapies that are now available for people with this type of cancer have fewer side effects than traditional chemotherapy and can improve survival and quality of life.
CONQUER CamLeukemiaPatient Stories
Joyce Beecher vividly recounts her cancer journey as a caregiver to her husband, Rich Beecher, who was diagnosed with chronic lymphocytic leukemia (CLL) in 2003. Listen to Joyce’s story as she describes their determination to find the best care and treatment for Rich, and encourages patients and caregivers to never give up.
CONQUER CamLeukemiaPatient Stories
Diagnosed in 2003, Rich Beecher has been living with chronic lymphocytic leukemia (CLL) for 15 years. Rich describes his cancer journey – from “Why me?” to focusing on the positive things in his life, including immersing himself more in photography.
Genetics & CancerLeukemia
Knowing if the patient’s chronic lymphocytic leukemia (CLL) has genetic abnormalities through genetic testing can help doctors select the best treatment.
FDA Approvals, News & UpdatesLeukemiaNewsworthy
In July 2018, the FDA approved Tibsovo (ivo-sidenib; from Agios Pharmaceuticals), the first IDH1 inhibitor, for the treatment of adults with relapsed (returning) or refractory (not responding to treatment) acute myeloid leukemia (AML) and a susceptible IDH1 genetic mutation.
Targeted Therapy Better Than Chemotherapy as First Treatment for Some Patients with Chronic Lymphocytic Leukemia
New findings show that starting with a targeted therapy regimen instead of chemotherapy improves outcomes for patients with chronic lymphocytic leukemia, particularly for those under age 70.
FDA Approvals, News & UpdatesLeukemia
FDA Approves Imbruvica plus Gazyva for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This new chemotherapy-free combination of Imbruvica, a targeted therapy, plus Gazyva, a CD20-directed cytolytic antibody, was recently approved by the FDA as first-line treatment of adults aged 65 or older who are newly diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Financial SupportLeukemiaPatient Stories
Martin Miralda was fresh out of college when a short visit to the United States helped to save his life after he was diagnosed with leukemia. Despite his lacking health insurance as a non-resident, he received superior medical care through “Charity Care,” a service that covers necessary hospitalization for uninsured people in the country and is available in several states.
Results of a recent study showed that using the targeted therapy Imbruvica (ibrutinib) as the first treatment in older adults with CLL was better than the combination of chemotherapy plus immunotherapy in slowing the progression of the disease.
Results 1 - 26 of 26